Navigation Links
Dr. Gil Ben-Menachem appointed Chief Executive Officer of OphthaliX Inc.
Date:12/12/2012

SOUTH JORDAN, Utah and PETACH TIKVAH, Israel, Dec. 12, 2012 /PRNewswire/ -- OphthaliX Inc. (OTCBB: OPLI) today announced that it has appointed Dr. Gil Ben-Menachem as Chief Executive Officer effective January 1, 2013. Dr. Ben-Menachem is a seasoned executive with twelve years of experience in the pharmaceutical, biotechnology, and venture capital industries.

Dr. Ben-Menachem joins OphthaliX from Teva Pharmaceutical Industries Ltd., a world leading generic drug maker, where he has served since 2008 as Director of Business Development at the Global Branded Products division.  At Teva, Dr. Ben-Menachem was responsible for business development efforts leading to partnering and acquisitions totaling over $500 million for late stage drug candidates.  Prior to that, he served as Director of Business Development at Paramount Bioscience LLC, a New York based drug development, life sciences merchant bank, and biotechnology venture capital firm, where he participated in the founding of several biotechnology companies.

Dr. Ben-Menachem received his B.Sc. in Biology, M.Sc. in Biotechnology, and Ph.D. in Microbiology from the Hebrew University, and his MBA from the University of Maryland. He concluded his postdoctoral training in immunology and microbiology at the NIH.

"I am honored and delighted to take this position at OphthaliX," commented Dr. Gil Ben-Menachem, upcoming Chief Executive Officer of OphthaliX. "With CF101 in Phase III for the treatment of Dry Eye Syndrome and in Phase II for the treatment of Glaucoma, OphthaliX represents a unique investment opportunity and I am excited to play a pivotal role in the development of innovative ophthalmic drugs for patients in need."

Prof. Pnina Fishman, Chairman of OphthaliX, commented, "This is a key appointment for OphthaliX and we are certain that Dr. Ben-Menachem's vast business and scientific experience combined with his strategic thinking, makes him the right person to drive the company to success over the coming years."

About OphthaliX Inc.

OphthaliX Inc. is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications, including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).

This release contains forward-looking statements regarding OphthaliX's future plans and expected performance based on assumptions the Company believes to be reasonable.  A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company's reports filed with the SEC.  In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company's control. OphthaliX undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE OphthaliX Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
2. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
3. John Saltamartine to Lead Operations as VR Laboratories Chief Operating Officer
4. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
5. Rhythm Names Lex Van der Ploeg Chief Scientific Officer
6. Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer
7. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
8. AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
9. Codexis Names Wes Bolsen VP and Chief Marketing Officer
10. Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... , ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” ... of Committee since 1987. Since then, he has served in a number of key ... for both the program and exposition committees. In his professional career, Dr. Gardner is ...
(Date:4/27/2016)... VANCOUVER, British Columbia , April 27, 2016 ... "Gesellschaft" oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... sie im Anschluss an ihre Pressemitteilung vom 13. ... Inc. erhalten hat, ihre Finanzen um zusätzliche 200.000.000 ... auf 4.000.000 Kanadische Dollar zu bringen. Davon wurden ...
(Date:4/27/2016)... Islands (PRWEB) , ... April 27, 2016 , ... ... Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief ... an Executive Director and one of the founding commercial leaders responsible for the ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a leading ... Dr. Lamka will assist PathSensors in expanding the use of the company’s CANARY® ... CANARY® test platform for the detection of harmful pathogens, including a number of ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):